Immune System

Adverse Effects of Engineered Nanomaterials

Volumn , Issue , 2012, Pages 169-184

  Boraschi, Diana ^a   Duschl, Albert ^b  

^a CNR   (Italy)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882766865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386940-1.00010-6     Document Type: Chapter

References (73)

1. Chappert P., Schwartz R.H. Induction of T cell anergy: Integration of environmental cues and infectious tolerance. Curr Opin Immunol 2010, 22:552-559.
2. Sakaguchi S. Regulatory T cells: History and perspective. Methods Mol Biol 2011, 707:3-17.
3. Fink S.L., Cookson B.T. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005, 73:1907-1916.
4. Aust A.E., Cook P.M., Dodson R.F. Morphological and chemical mechanisms of elongated mineral particle toxicities. J Toxicol Environ Health B Crit Rev 2011, 14:40-75.
5. Johnston H.J., Hutchison G.R., Christensen F.M., et al. A critical review of the biological mechanisms underlying the in vivo and in vitro toxicity of carbon nanotubes: The contribution of physico-chemical characteristics. Nanotoxicology 2010, 4:207-246.
6. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
7. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: Challenges, solutions and future prospects. Curr Pharm Des 2010, 16:2298-2307.
8. Reisetter A.C., Stebounova L.V., Baltrusaitis J., et al. Induction of inflammasome dependent pyroptosis by carbon black nanoparticles. J Biol Chem 2011, 286:21844-21852.
9. Witasp E., Shvedova A.A., Kagan V.E., Fadeel B. Single-walled carbon nanotubes impair human macrophage engulfment of apoptotic cell corpses. Inhal Toxicol 2009, 21(Suppl. 1):131-136.
10. Valledor A.F., Comalada M., Santamaria-Babi L.F., Lloberas J., Celada A. Macrophage proinflammatory activation and deactivation: A question of balance. Adv Immunol 2010, 108:1-20.
11. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
12. De Koker S., Lambrecht B.N., Willart M.A., et al. Designing polymeric particles for antigen delivery. Chem Soc Rev 2011, 40:320-339.
13. Xiang S.D., Selomulya C., Ho J., Apostolopoulos V., Plebanski M. Delivery of DNA vaccines: An overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:205-218.
14. Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-McDonagh M.M., Ficht T.A. Polymeric particles in vaccine delivery. Curr Opin Microbiol 2010, 13:106-112.
15. Fadeel B., Garcia-Bennett A.E. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010, 62:362-374.
16. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
17. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181:17-21.
18. Hornung V., Bauernfeind F., Halle A., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
19. Sutterwala F.S., Ogura Y., Flavell R.A. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007, 82:259-264.
20. Franchi L., Eigenbrod T., Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009, 183:792-796.
21. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007, 14:10-22.
22. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010, 40:616-619.
23. Monopoli M.P., Walczyk D., Campbell A., et al. Physical-chemical aspects of protein corona: Relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011, 133:2525-2534.
24. Maiorano G., Sabella S., Sorce B., et al. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano 2010, 4:7481-7491.
25. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
26. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010, 5:e10949.
27. Rocker C., Potzl M., Zhang F., Parak W.J., Nienhaus G.U. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat Nanotechnol 2009, 4:577-580.
28. Vauthier C., Lindner P., Cabane B. Configuration of bovine serum albumin adsorbed on polymer particles with grafted dextran corona. Colloids Surf B Biointerfaces 2009, 69:207-215.
29. Wallberg M., Bergquist J., Achour A., Breij E., Harris R.A. Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol 2007, 37:1986-1995.
30. Qiao S.W., Bergseng E., Molberg O., Jung G., Fleckenstein B., Sollid L.M. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: Importance of proline spacing and glutamine deamidation. J Immunol 2005, 175:254-261.
31. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1 0401 MHC class II molecule. J Immunol 2003, 171:538-541.
32. Moss C.X., Matthews S.P., Lamont D.J., Watts C. Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J Biol Chem 2005, 280:18498-18503.
33. Deng Z.J., Liang M., Monteiro M., Toth I., Minchin R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol 2011, 6:39-44.
34. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-275.
35. Nagai H., Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: Lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys 2010, 502:1-7.
36. Kunzmann A., Andersson B., Vogt C., et al. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol 2011, 253:81-93.
37. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 2010, 23:207-217.
38. Groves E., Dart A.E., Covarelli V., Caron E. Molecular mechanisms of phagocytic uptake in mammalian cells. Cell Mol Life Sci 2008, 65:1957-1976.
39. Munoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6:280-289.
40. Heinrich J. Influence of indoor factors in dwellings on the development of childhood asthma. Int J Hyg Environ Health 2011, 214:1-25.
41. Holgate S.T., Lack G. Improving the management of atopic disease. Arch Dis Child 2005, 90:826-831.
42. Nel A.E., Diaz-Sanchez D., Ng D., Hiura T., Saxon A. Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. J Allergy Clin Immunol 1998, 102:539-554.
43. van Zijverden M., Granum B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology 2000, 152:69-77.
44. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-839.
45. Duschl A. Nanoparticle effects on the immune system. Nanotoxicology. Interactions of nanomaterials with biological systems 2007, 144-165. American Scientific Publishers, Stevenson Ranch. Y.N. Zhang (Ed.).
46. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-246.
47. Li N., Xia T., Nel A.E. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44:1689-1699.
48. Larsen S.T., Roursgaard M., Jensen K.A., Nielsen G.D. Nano titanium dioxide particles promote allergic sensitization and lung inflammation in mice. Basic Clin Pharmacol Toxicol 2010, 106:114-117.
49. 2 particles inhibits features of allergic asthma in a murine model. Part Fibre Toxicol 2010, 7:35.
50. Nygaard U.C., Hansen J.S., Samuelsen M., Alberg T., Marioara C.D., Lovik M. Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. Toxicol Sci 2009, 109:113-123.
51. Scholl I., Weissenbock A., Forster-Waldl E., et al. Allergen-loaded biodegradable poly(D, L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004, 34:315-321.
52. Park H.S., Kim K.H., Jang S., et al. Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles. Int J Nanomed 2010, 5:505-515.
53. Vemula P.K., Anderson R.R., Karp J.M. Nanoparticles reduce nickel allergy by capturing metal ions. Nat Nanotechnol 2011, 6:291-295.
54. Robertson T.A., Sanchez W.Y., Roberts M.S. Are commercially available nanoparticles safe when applied to the skin?. J Biomed Nanotechnol 2010, 6:452-468.
55. Wiechers J.W., Musee N. Engineered inorganic nanoparticles and cosmetics: Facts, issues, knowledge gaps and challenges. J Biomed Nanotechnol 2010, 6:408-431.
56. Shea K.M., Truckner R.T., Weber R.W., Peden D.B. Climate change and allergic disease. J Allergy Clin Immunol 2008, 122:443-453. quiz 454-455.
57. Salvador-Morales C., Flahaut E., Sim E., Sloan J., Green M.L., Sim R.B. Complement activation and protein adsorption by carbon nanotubes. Mol Immunol 2006, 43:193-201.
58. Dobrovolskaia M.A., Patri A.K., Zheng J., et al. Interaction of colloidal gold nanoparticles with human blood: Effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2009, 5:106-117.
59. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
60. Sim R.B., Wallis R. Surface properties: Immune attack on nanoparticles. Nat Nanotechnol 2011, 6:80-81.
61. Mosqueira V.C., Legrand P., Gulik A., et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001, 22:2967-2979.
62. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 2006, 78:620-628.
63. Al-Hanbali O., Rutt K.J., Sarker D.K., Hunter A.C., Moghimi S.M. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol 2006, 6:3126-3133.
64. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: Implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
65. Chanan-Khan A., Szebeni J., Savay S., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): Possible role in hypersensitivity reactions. Ann Oncol 2003, 14:1430-1437.
66. Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol 2007, 297:353-363.
67. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001, 13:85-94.
68. Oostingh G.J., Casals E., Italiani P., et al. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part Fibre Toxicol 2011, 8:8.
69. Shi Y., Yadav S., Wang F., Wang H. Endotoxin promotes adverse effects of amorphous silica nanoparticles on lung epithelial cells in vitro. J Toxicol Environ Health A 2010, 73:748-756.
70. Dobrovolskaia M.A., Neun B.W., Clogston J.D., Ding H., Ljubimova J., McNeil S.E. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) 2010, 5:555-562.
71. Neun B.W., Dobrovolskaia M.A. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Meth Mol Biol 2011, 697:121-130.
72. Vallhov H., Qin J., Johansson S.M., et al. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett 2006, 6:1682-1686.
73. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11:1014-1022.